Vasoflux International Trial for Acute Myocardial Infarction Lysis - VITAL

Description:

Vasoflux International Trial for Acute Myocardial Infarction Lysis (VITAL) was a randomized, single-blind, phase 2, dose-escalating, multicenter trial of the vasoflux versus unfractionated heparin (UFH) in patients with acute ST-segment elevation myocardial infarction (MI) undergoing treatment with streptokinase. Vasoflux is a novel anticoagulant, derived from low-molecular-weight heparin and chemically modified to have decreased factor Xa activity and increased affinity for factor IXa and hepar...